Morgan Stanley
KLRS

Morgan Stanley’s Kalaris Therapeutics KLRS Stock Holding History

Morgan Stanley’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$294K Buy
72,326
+33,982
+89% +$176K ﹤0.01% 5785
2026
Q1 		$221K Buy
38,344
+10,396
+37% +$92.3K ﹤0.01% 5828
2025
Q4 		$236K Buy
27,948
+3,030
+12% +$19.4K ﹤0.01% 5867
2025
Q3 		$144K Buy
24,918
+22,954
+1,169% +$75.9K ﹤0.01% 6012
2025
Q2 		$5.24K Buy
1,964
+668
+52% +$3.02K ﹤0.01% 7021
2025
Q1 		$10.4K Buy
1,296
+299
+30% +$2.93K ﹤0.01% 6786
2024
Q4 		$9.63K Sell
997
-1,063
-52% -$16.1K ﹤0.01% 6819
2024
Q3 		$38.3K Sell
2,060
-981
-32% -$17.2K ﹤0.01% 6287
2024
Q2 		$50.6K Sell
3,041
-12,338
-80% -$218K ﹤0.01% 6163
2024
Q1 		$267K Sell
15,379
-6,904
-31% -$113K ﹤0.01% 5610
2023
Q4 		$348K Sell
22,283
-1,790
-7% -$70.6K ﹤0.01% 5473
2023
Q3 		$1.19M Buy
24,073
+12,228
+103% +$833K ﹤0.01% 4695
2023
Q2 		$926K Buy
11,845
+3,722
+46% +$354K ﹤0.01% 4877
2023
Q1 		$736K Sell
8,123
-1,687
-17% -$215K ﹤0.01% 5041
2022
Q4 		$1.16M Sell
9,810
-7,692
-44% -$1.3M ﹤0.01% 4788
2022
Q3 		$3.17M Buy
17,502
+11,362
+185% +$1.77M ﹤0.01% 4060
2022
Q2 		$551K Buy
6,140
+2,137
+53% +$224K ﹤0.01% 5366
2022
Q1 		$622K Buy
4,003
+1,884
+89% +$376K ﹤0.01% 5279
2021
Q4 		$632K Sell
2,119
-239
-10% -$111K ﹤0.01% 5404
2021
Q3 		$1.36M Buy
2,358
+343
+17% +$159K ﹤0.01% 4852
2021
Q2 		$914K Sell
2,015
-1,160
-37% -$599K ﹤0.01% 5133
2021
Q1 		$1.71M Buy
3,175
+1,250
+65% +$1.05M ﹤0.01% 4377
2020
Q4 		$1.7M Buy
1,925
+1,735
+913% +$1.33M ﹤0.01% 4285
2020
Q3 		$120K Buy
+190
New +$130K ﹤0.01% 5346

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley's KLRS Position: Q2 2026 in Review

Morgan Stanley increased its Kalaris Therapeutics (KLRS) stake by 89% in Q2 2026, buying an estimated $176K and bringing the position to 72,326 shares worth $294K. The position accounts for ﹤0.01% of the portfolio, ranked #5785.

Morgan Stanley first reported a position in KLRS in Q3 2020 and has held it in 24 quarters since. The position peaked at $3.17M in Q3 2022. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Morgan Stanley held 72,326 shares of Kalaris Therapeutics worth $294K as of Q2 2026.
  • Morgan Stanley bought 33,982 Kalaris Therapeutics shares in Q2 2026, an estimated $176K.
  • Kalaris Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5785 holding.
  • Morgan Stanley first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Morgan Stanley's Kalaris Therapeutics position peaked at $3.17M in Q3 2022.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.